688319 欧林生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-3.1081.9523.07917.67510.070
总资产报酬率 ROA (%)-1.7061.1361.97511.6526.399
投入资产回报率 ROIC (%)-2.3241.6022.76316.5607.888

边际利润分析
销售毛利率 (%)94.56393.55092.86593.92795.140
营业利润率 (%)-14.0290.6257.60120.85210.349
息税前利润/营业总收入 (%)-11.0934.0918.21221.99111.477
净利润/营业总收入 (%)-13.5762.3064.85422.16211.287

收益指标分析
经营活动净收益/利润总额(%)59.33233.73167.60994.90697.241
价值变动净收益/利润总额(%)-0.5826.6718.4783.5120.595
营业外收支净额/利润总额(%)-3.33680.1594.6565.2318.309

偿债能力分析
流动比率 (X)1.8281.9551.7822.5611.513
速动比率 (X)1.6521.8041.6322.3431.321
资产负债率 (%)46.36742.28239.69430.30241.214
带息债务/全部投入资本 (%)26.64218.65811.3032.665--
股东权益/带息债务 (%)266.140422.883757.4133,545.2454,472.123
股东权益/负债合计 (%)114.231134.475150.186230.013142.637
利息保障倍数 (X)-4.4684.33534.304-1,787.57960.488

营运能力分析
应收账款周转天数 (天)390.889356.438272.293194.9810.000
存货周转天数 (天)1,152.097847.387705.108733.2000.000